Abstract
7036 Background: A phase II trial was conducted to evaluate the activity of single agent cetuximab in patients (pts) with recurrent NSCLC. Preliminary data was previously reported (Lynch, et al, ab...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
